Shukra [SHUKRAPHAR] vs Sequent Scientific [SEQUENT] Detailed Stock Comparison
Shukra
BSE
Loading...
Sequent Scientific
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Shukra wins in 10 metrics, Sequent Scientific wins in 8 metrics, with 0 ties. Shukra appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Shukra | Sequent Scientific | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 83.45 | 202.31 | Shukra |
| Price-to-Book Ratio | 13.11 | 6.17 | Sequent Scientific |
| Debt-to-Equity Ratio | 6.65 | 62.47 | Shukra |
| PEG Ratio | N/A | 34.45 | N/A |
| EV/EBITDA | 49.17 | 29.60 | Sequent Scientific |
| Profit Margin (TTM) | 26.02% | 1.41% | Shukra |
| Operating Margin (TTM) | 53.21% | 9.41% | Shukra |
| EBITDA Margin (TTM) | 53.21% | 9.41% | Shukra |
| Return on Equity | 15.90% | 4.35% | Shukra |
| Return on Assets (TTM) | 10.58% | 4.01% | Shukra |
| Free Cash Flow (TTM) | $51.75M | $442.70M | Sequent Scientific |
| Dividend Yield | 7.26% | N/A | N/A |
| 1-Year Return | 193.29% | 23.40% | Shukra |
| Price-to-Sales Ratio (TTM) | 21.85 | 2.81 | Sequent Scientific |
| Enterprise Value | $8.33B | $46.83B | Sequent Scientific |
| EV/Revenue Ratio | 22.63 | 3.02 | Sequent Scientific |
| Gross Profit Margin (TTM) | 86.72% | 50.28% | Shukra |
| Revenue per Share (TTM) | $1 | $62 | Sequent Scientific |
| Earnings per Share (Diluted) | $0.22 | $0.86 | Sequent Scientific |
| Beta (Stock Volatility) | 0.33 | 0.91 | Shukra |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Shukra vs Sequent Scientific Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Shukra | -1.98% | -9.47% | -9.78% | 51.86% | -16.36% | 28.30% |
| Sequent Scientific | 5.23% | 2.39% | -4.06% | 4.50% | 16.44% | -4.24% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Shukra | 193.29% | 295.69% | 1,717.82% | 1,019.51% | 394.88% | 394.88% |
| Sequent Scientific | 23.40% | 60.75% | 35.04% | 19.94% | 19.94% | 19.94% |
Performance & Financial Health Analysis: Shukra vs Sequent Scientific
| Metric | SHUKRAPHAR | SEQUENT |
|---|---|---|
| Market Information | ||
| Market Cap | ₹8.04B | ₹43.53B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 91,148 | 674,091 |
| 90 Day Avg. Volume | 190,256 | 529,812 |
| Last Close | ₹18.36 | ₹176.83 |
| 52 Week Range | ₹5.75 - ₹27.15 | ₹117.35 - ₹240.70 |
| % from 52W High | -32.38% | -26.54% |
| All-Time High | ₹27.15 (Mar 03, 2025) | ₹336.50 (Jun 28, 2021) |
| % from All-Time High | -32.38% | -47.45% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.30% | 0.11% |
| Quarterly Earnings Growth | 0.35% | 0.12% |
| Financial Health | ||
| Profit Margin (TTM) | 0.26% | 0.01% |
| Operating Margin (TTM) | 0.53% | 0.09% |
| Return on Equity (TTM) | 0.16% | 0.04% |
| Debt to Equity (MRQ) | 6.65 | 62.47 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹1.40 | ₹28.19 |
| Cash per Share (MRQ) | ₹0.27 | ₹2.52 |
| Operating Cash Flow (TTM) | ₹79.18M | ₹833.62M |
| Levered Free Cash Flow (TTM) | ₹41.04M | ₹453.76M |
| Dividends | ||
| Last 12-Month Dividend Yield | 7.26% | N/A |
| Last 12-Month Dividend | ₹1.00 | ₹0.00 |
Valuation & Enterprise Metrics Analysis: Shukra vs Sequent Scientific
| Metric | SHUKRAPHAR | SEQUENT |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 83.45 | 202.31 |
| Forward P/E | N/A | 34.45 |
| PEG Ratio | N/A | 34.45 |
| Price to Sales (TTM) | 21.85 | 2.81 |
| Price to Book (MRQ) | 13.11 | 6.17 |
| Market Capitalization | ||
| Market Capitalization | ₹8.04B | ₹43.53B |
| Enterprise Value | ₹8.33B | ₹46.83B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 22.63 | 3.02 |
| Enterprise to EBITDA | 49.17 | 29.60 |
| Risk & Other Metrics | ||
| Beta | 0.33 | 0.91 |
| Book Value per Share (MRQ) | ₹1.40 | ₹28.19 |
Financial Statements Comparison: Shukra vs Sequent Scientific
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | SHUKRAPHAR | SEQUENT |
|---|---|---|
| Revenue/Sales | ₹132.70M | ₹4.02B |
| Cost of Goods Sold | ₹17.63M | ₹2.00B |
| Gross Profit | ₹115.07M | ₹2.02B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹63.76M | ₹294.80M |
| EBITDA | ₹87.85M | ₹442.10M |
| Pre-Tax Income | ₹75.70M | ₹163.10M |
| Income Tax | ₹21.84M | ₹59.30M |
| Net Income (Profit) | ₹53.86M | ₹103.80M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | SHUKRAPHAR | SEQUENT |
|---|---|---|
| Cash & Equivalents | N/A | ₹626.60M |
| Total Current Assets | ₹654.27M | ₹8.74B |
| Total Current Liabilities | ₹172.84M | ₹5.05B |
| Long-Term Debt | ₹31.13M | ₹3.00B |
| Total Shareholders Equity | ₹628.36M | ₹7.70B |
| Retained Earnings | N/A | N/A |
| Property, Plant & Equipment | ₹193.97M | ₹2.84B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | SHUKRAPHAR | SEQUENT |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | SHUKRAPHAR | SEQUENT |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 91,148 | 674,091 |
| Average Daily Volume (90 Day) | 190,256 | 529,812 |
| Shares Outstanding | 437.88M | 249.89M |
| Float Shares | 47.92M | 117.77M |
| % Held by Insiders | 0.89% | 0.53% |
| % Held by Institutions | 0.00% | 0.13% |
Dividend Analysis & Yield Comparison: Shukra vs Sequent Scientific
| Metric | SHUKRAPHAR | SEQUENT |
|---|---|---|
| Last 12-Month Dividend | ₹1.00 | ₹0.00 |
| Last 12-Month Dividend Yield | 7.26% | N/A |
| 3-Year Avg Annual Dividend | ₹0.35 | ₹0.00 |
| 3-Year Avg Dividend Yield | 5.23% | N/A |
| 3-Year Total Dividends | ₹1.04 | ₹0.00 |
| Ex-Dividend Date | Sep 23, 2024 | N/A |